Pipeline

SH-201

A treatment for Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS and Gastrointestinal tumors.

Disease state overview

  • Chronic Myeloid Leukemia (approximately 8,930 patients in the US diagnosed per year)1
  • Acute Lymphoblastic Leukemia (approximately 6,660 patients in the US diagnosed per year)2
  • Myelodysplastic/myeloproliferative diseases (approximately 20,000 patients in the US diagnosed per year)3
  • Gastrointestinal tumours (approximately 38,570 patients in the US diagnosed per year)1

Regulatory Status

Shorla Oncology have entered into a licensing agreement and strategic partnership to obtain an exclusive license to register and commercialize SH-201, the first palatable oral solution of the related chemotherapeutic agent in the U.S. SH-201 is an oral solution treatment that slows or stops the growth of certain forms of leukemia (such as acute lymphoblastic leukemia and chronic myeloid leukemia). The NDA submission is planned for Q1 2024.

1American Cancer Society. Cancer Facts & Figures, 2023.

2American Cancer Society. Cancer Facts & Figures, 2022.

3Incidence and Prevalence of MDS Across Patient Populations 2022 (ajmc.com)